Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease
Authors Hager K, Baseman A, Nye JS, Brashear HR, Han J, Sano M, Davis B, Richards H
Received 20 November 2013
Accepted for publication 15 January 2014
Published 21 February 2014 Volume 2014:10 Pages 391—401
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Klaus Hager,1 Alan S Baseman,2 Jeffrey S Nye,2 H Robert Brashear,2 John Han,2 Mary Sano,3 Bonnie Davis,4 Henry M Richards2
1Clinic for Medicine of the Elderly, Hannover, Germany; 2Janssen Research and Development, LLC, Raritan, NJ, USA; 3The Mount Sinai Medical Center, New York, NY, USA; 4Synaptec Inc., Palm Beach Gardens, FL, USA
Background: Currently available treatments for Alzheimer's disease (AD) can produce mild improvements in cognitive function, behavior, and activities of daily living in patients, but their influence on long-term survival is not well established. This study was designed to assess patient survival and drug efficacy following a 2-year galantamine treatment in patients with mild to moderately severe AD.
Methods: In this multicenter, double-blind study, patients were randomized 1:1 to receive galantamine or placebo. One primary end point was safety; mortality was assessed. An independent Data Safety Monitoring Board monitored mortality for the total deaths reaching prespecified numbers, using a time-to-event method and a Cox-regression model. The primary efficacy end point was cognitive change from baseline to month 24, as measured by the Mini-Mental State Examination (MMSE) score, analyzed using intent-to-treat analysis with the 'last observation carried forward' approach, in an analysis of covariance model.
Results: In all, 1,024 galantamine- and 1,021 placebo-treated patients received study drug, with mean age ~73 years, and mean (standard deviation [SD]) baseline MMSE score of 19 (4.08). A total of 32% of patients (661/2,045) completed the study, 27% (554/2,045) withdrew, and 41% (830/2,045) did not complete the study and were discontinued due to a Data Safety Monitoring Board-recommended early study termination. The mortality rate was significantly lower in the galantamine group versus placebo (hazard ratio [HR] =0.58; 95% confidence interval [CI]: 0.37; 0.89) (P=0.011). Cognitive impairment, based on the mean (SD) change in MMSE scores from baseline to month 24, significantly worsened in the placebo (-2.14 [4.34]) compared with the galantamine group (-1.41 [4.05]) (P<0.001). Functional impairment, based on mean (SD) change in the Disability Assessment in Dementia score (secondary end point), at month 24 significantly worsened in the placebo (-10.81 [18.27]) versus the galantamine group (-8.16 [17.25]) (P=0.002). Incidences of treatment-emergent adverse events were 54.0% for the galantamine and 48.6% for the placebo group.
Conclusion: Long-term treatment with galantamine significantly reduced mortality and the decline in cognition and daily living activities, in mild to moderate AD patients.
Identification: This study is registered at ClinicalTrials.gov (NCT00679627).
Keywords: cholinesterase inhibitors, cognition, long-term treatment, mortality, nicotinic
Corrigendum for this article has been published
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]